Jianyong Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jianyong Li has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
Wei Xu
Department of Hematology, Pukou CLL Center, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine
2 shared publicationsWei Zhang
Peking Union Medical College Hospital, Hematology Department
2 shared publicationsYongping Song
Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital
2 shared publicationsBing Xu
The First Affiliated Hospital of Xiamen University, Hematology Department
1 shared publicationChunyan Ji
Qilu Hospital, Shandong University, Hematology Department
1 shared publicationHuilai Zhang
Tianjin Medical University Cancer Institute & Hospital, Lymphoma
1 shared publication
Latest Publications
- Open Access
- 23 September 2022
- Published by Springer Nature in Research Square
Orelabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Patients: Multi-center, Single-arm, Open-label, Phase 2 Study
Background Orelabrutinib is a novel, small molecule, selective irreversible Bruton’s tyrosine kinase inhibitor. The aim of this study was to evaluate the efficacy as well as safety in patients with refractory or relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma (R/R CLL/SLL). Methods This is single-arm, multi-center, open-label, phase 2 study in 80 eligible Chinese patients, who were treated with monotherapy of orelabrutinib at 150 mg once daily. Overall response rate (ORR) that was evaluated by an independent review committee (IRC) was set as the study’s primary endpoint, with progression-free survival (PFS), overall survival (OS), and safety as the study’s major secondary endpoints. Results IRC-assessed ORR was 92.5% (74/80); complete response 21.3% (17/80), partial response 60.0% (48/80), partial response with lymphocytosis 11.3% (9/80). At a 32.3-month median follow-up (mFu), the median PFS had not been achieved, while the 30-month PFS rate and OS rate were 70.9% (95% confidence interval [CI], 59.5-79.6) and 81.3% (95% CI, 70.8-88.2), respectively. Orelabrutinib also revealed substantial response in patients with high prognostic risks: ORRs of patients carrying positive TP53 mutational status or del(17p), del(11q), as well as unmutated immunoglobulin heavy-chain variable region gene (IGHV) were 100%, 94.7%, and 93.9%, respectively. Most adverse events (AEs) were in low grade, with 86.8% of AEs being Grade 1 or 2. Nearly 67% of patients were still receiving orelabrutinib after almost a 3-year follow-up. Conclusions Orelabrutinib demonstrated compelling efficacy as well as safety profiles, with a noteworthy number of patients obtaining complete response in R/R CLL/SLL. Trial registration The study (NCT03493217) has been registered at ClinicalTrials.gov.
- 23 September 2022
- Published by Springer Nature in Research Square
Open AccessOrelabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Patients: Multi-center, Single-arm, Open-label, Phase 2 Study
Background Orelabrutinib is a novel, small molecule, selective irreversible Bruton’s tyrosine kinase inhibitor. The aim of this study was to evaluate the efficacy as well as safety in patients with refractory or relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma (R/R CLL/SLL). Methods This is single-arm, multi-center, open-label, phase 2 study in 80 eligible Chinese patients, who were treated with monotherapy of orelabrutinib at 150 mg once daily. Overall response rate (ORR) that was evaluated by an independent review committee (IRC) was set as the study’s primary endpoint, with progression-free survival (PFS), overall survival (OS), and safety as the study’s major secondary endpoints. Results IRC-assessed ORR was 92.5% (74/80); complete response 21.3% (17/80), partial response 60.0% (48/80), partial response with lymphocytosis 11.3% (9/80). At a 32.3-month median follow-up (mFu), the median PFS had not been achieved, while the 30-month PFS rate and OS rate were 70.9% (95% confidence interval [CI], 59.5-79.6) and 81.3% (95% CI, 70.8-88.2), respectively. Orelabrutinib also revealed substantial response in patients with high prognostic risks: ORRs of patients carrying positive TP53 mutational status or del(17p), del(11q), as well as unmutated immunoglobulin heavy-chain variable region gene (IGHV) were 100%, 94.7%, and 93.9%, respectively. Most adverse events (AEs) were in low grade, with 86.8% of AEs being Grade 1 or 2. Nearly 67% of patients were still receiving orelabrutinib after almost a 3-year follow-up. Conclusions Orelabrutinib demonstrated compelling efficacy as well as safety profiles, with a noteworthy number of patients obtaining complete response in R/R CLL/SLL. Trial registration The study (NCT03493217) has been registered at ClinicalTrials.gov.
- Open Access
- 27 October 2021
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 6 (1) , 1-7
Sintilimab for relapsed/refractory extranodal NK/T cell lymphoma: a multicenter, single-arm, phase 2 trial (ORIENT-4)
This study (ORIENT-4) aimed to assess the efficacy and safety of sintilimab, a humanized anti-PD-1 antibody, in patients with relapsed/refractory extranodal NK/T cell lymphoma (r/r ENKTL). ORIENT-4 is a multicenter, single-arm, phase 2 clinical trial (NCT03228836). Patients with r/r ENKTL who failed to at least one asparaginase-based regimen were enrolled to receive sintilimab 200 mg intravenously every 3 weeks for up to 24 months. The primary endpoint was the objective response rate (ORR) based on Lugano 2014 criteria. Twenty-eight patients with r/r ENKTL were enrolled from August 31, 2017 to February 7, 2018. Twenty-one patients (75.0%, 95% CI: 55.1–89.3%) achieved an objective response. With a median follow-up of 30.4 months, the median overall survival (OS) was not reached. The 24-month OS rate was 78.6% (95% CI, 58.4–89.8%). Most treatment-related adverse events (TRAEs) were grade 1–2 (71.4%), and the most common TRAE was decreased lymphocyte count (42.9%). Serious adverse events (SAEs) occurred in 7 (25.0%) patients, and no patient died of adverse events. Sintilimab is effective and well tolerated in patients with r/r ENKTL and could be a novel therapeutic approach for the control of ENKTL in patients.
- 27 October 2021
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 6 (1) , 1-7
Open AccessSintilimab for relapsed/refractory extranodal NK/T cell lymphoma: a multicenter, single-arm, phase 2 trial (ORIENT-4)
This study (ORIENT-4) aimed to assess the efficacy and safety of sintilimab, a humanized anti-PD-1 antibody, in patients with relapsed/refractory extranodal NK/T cell lymphoma (r/r ENKTL). ORIENT-4 is a multicenter, single-arm, phase 2 clinical trial (NCT03228836). Patients with r/r ENKTL who failed to at least one asparaginase-based regimen were enrolled to receive sintilimab 200 mg intravenously every 3 weeks for up to 24 months. The primary endpoint was the objective response rate (ORR) based on Lugano 2014 criteria. Twenty-eight patients with r/r ENKTL were enrolled from August 31, 2017 to February 7, 2018. Twenty-one patients (75.0%, 95% CI: 55.1–89.3%) achieved an objective response. With a median follow-up of 30.4 months, the median overall survival (OS) was not reached. The 24-month OS rate was 78.6% (95% CI, 58.4–89.8%). Most treatment-related adverse events (TRAEs) were grade 1–2 (71.4%), and the most common TRAE was decreased lymphocyte count (42.9%). Serious adverse events (SAEs) occurred in 7 (25.0%) patients, and no patient died of adverse events. Sintilimab is effective and well tolerated in patients with r/r ENKTL and could be a novel therapeutic approach for the control of ENKTL in patients.